CorMedix Inc. Files 8-K on Financials
Ticker: CRMD · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1410098
| Field | Detail |
|---|---|
| Company | Cormedix Inc. (CRMD) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
CorMedix filed an 8-K detailing financial results and exhibits.
AI Summary
CorMedix Inc. filed an 8-K on January 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. CorMedix Inc. is incorporated in Delaware and its principal executive offices are located in Berkeley Heights, New Jersey.
Why It Matters
This filing provides an update on CorMedix Inc.'s financial health and operational results, which is crucial information for investors and stakeholders to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing (8-K) and does not contain new material events or significant changes.
Key Players & Entities
- CorMedix Inc. (company) — Registrant
- January 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Berkeley Heights, New Jersey (location) — Principal Executive Offices
- 001-34673 (identifier) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on CorMedix Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 7, 2025.
In which state is CorMedix Inc. incorporated?
CorMedix Inc. is incorporated in Delaware.
What is the address of CorMedix Inc.'s principal executive offices?
The address of CorMedix Inc.'s principal executive offices is 300 Connell Drive, Suite 4200, Berkeley Heights, New Jersey 07922.
What is CorMedix Inc.'s telephone number?
CorMedix Inc.'s telephone number, including area code, is (908) 517-9500.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-07 08:00:07
Key Financial Figures
- $0.001 — ge on which registered) Common Stock, $0.001 Par Value CRMD Nasdaq Global Market
Filing Documents
- ea0226957-8k_cormedix.htm (8-K) — 29KB
- ea022695701ex99-1_cormedix.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 10KB
- 0001213900-25-001392.txt ( ) — 235KB
- crmd-20250107.xsd (EX-101.SCH) — 3KB
- crmd-20250107_lab.xml (EX-101.LAB) — 33KB
- crmd-20250107_pre.xml (EX-101.PRE) — 22KB
- ea0226957-8k_cormedix_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 7, 2025, CorMedix Inc. (the "Company") issued a press release announcing its preliminary financial results for the quarter and year ended December 31, 2024 and provided a business update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by CorMedix Inc., dated January 7, 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). - 1 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 7, 2025 CORMEDIX INC. By: /s/ Joseph Todisco Joseph Todisco Chief Executive Officer - 2 -